Nyxoah Announces Preliminary Results for the Second Quarter of 2025
Nyxoah Announces Preliminary Results for the Second Quarter of 2025 Mont-Saint-Guibert, Belgium – August 11, 2025, 7:00am CET / 1:00am...
Clinical Trial
Amphastar Announces FDA Approval for Iron Sucrose Injection, USP
According to the FDA, Amphastar's iron sucrose injection meets the criteria for bioequivalence and therapeutic equivalence to Venofer® for the...
Trump May Reclassify Marijuana – MMJ BioPharma To Escape The DEA’s Seven Year Cannabis Trial Roadblock?
Trump said his administration will focus on research to unlock the medical uses of marijuana, and other priorities the marijuana...
HistoIndex Marks Another Step Forward with FibroSIGHT™ Plus: Introducing AI-based Quantitative Analysis in Fibrosis Assessment
SINGAPORE, Aug. 10, 2025 /PRNewswire/ -- HistoIndex, a pioneering leader in digital pathology solutions for chronic liver disease, has announced...
IO Biotech to Announce Topline Results of Pivotal Phase 3 Trial of Cylembio® in Combination with KEYTRUDA® (pembrolizumab) as a First-Line Treatment for Patients with Advanced Melanoma
NEW YORK, Aug. 10, 2025 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company, today announced the company...
TERRY COLE FIX IT! DEA Blocks FDA Cannabis Trials While Contaminated Marijuana Floods State Markets
Terrance Cole's Choice: Reformer or Cover-Up Artist? New DEA Administrator Terrance Cole stands at a crossroads:Break rank, clean house, and...
XORTX Completes USD $114,500 Private Placement
NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICESOR FOR DISSEMINATION IN THE UNITED STATES CALGARY, Alberta, Aug. 08, 2025...
Capricor Therapeutics Announces Type A Meeting Scheduled with U.S. FDA
– Second Quarter 2025 Financial Results and Corporate Update Rescheduled to Monday, August 11, 2025, at 4:30 p.m. ET –SAN...
KALA BIO Reports Second Quarter 2025 Financial Results and Provides Corporate Update
-- Completed patient enrollment in Phase 2b CHASE trial of KPI-012 in Persistent Corneal Epithelial Defect (PCED); topline data expected...
CG Oncology Reports Second Quarter 2025 Financial Results and Provides Business Updates
- Announced best-in-disease durability data in BOND-003 Cohort C and promising early signal in Cohort P for cretostimogene grenadenorepvec at...
Junshi Biosciences Announces the Acceptance of the sNDA for Toripalimab as the 1st-line Treatment of HER2-expressing Urothelial Carcinoma
SHANGHAI, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading...
Spectral Medical Announces Second Quarter and Provides Corporate Update
Topline Tigris results expected to be released around mid-August 2025 TORONTO, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Spectral Medical Inc....
Akero Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
Published results from the 96-Week Phase 2b SYMMETRY trial in the New England Journal of Medicine Three presentations at the...
ANI Pharmaceuticals Reports Record Second Quarter 2025 Financial Results and Raises 2025 Guidance
Generated record quarterly net revenues of $211.4 million, representing year-over-year growth of 53.1% on a reported basis and 37.0% on...
Y-mAbs Reports Second Quarter 2025 Financial Results and Recent Corporate Developments
Reported Total Revenues of $19.5 million for the second quarter of 2025, exceeding the high end of the Company’s guidance...
Nxera Pharma Operational Highlights and Consolidated Results for the Second Quarter and First Half 2025
Tokyo, Japan and Cambridge, UK, 8 August 2025 – Nxera Pharma (“the Company” or “Nxera”; TSE: 4565) provides an update...
Believe Limited, LLC and Meraki Social, LLC Join Forces to Launch “Narrative Influence™” — A Bold New Era of Sustained Storytelling for Health, Wellness, and Rare Disease Communities
LOS ANGELES and SAUGATUCK, Mich., Aug. 7, 2025 /PRNewswire/ -- Today, Believe Limited, LLC, and Meraki Social, LLC officially announce...
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 2025
- Reports Net Revenues of $174.4 million for the Three Months Ended June 30, 2025- GAAP net income of $31.0...
Brain Computer Interface Market to Soar from USD 1.6 Billion in 2024 to USD 6.3 Billion by 2033, at 20.5% CAGR – Market Research Intellect
The Brain Computer Interface (BCI) market is experiencing rapid growth due to increasing advancements in neurotechnology, rising demand for assistive...
Survey Finds Patients Prefer Remote Trials but Want Simple, Trusted Wearables to Participate
Insights from Vivalink's survey help sponsors and CROs design trials that improve participation and retention CAMPBELL, Calif., Aug. 7, 2025...